biomedicines

IMPACT FACTOR 4.7

Indexed in: PubMed

CITESCORE 3.7

an Open Access Journal by MDPI

Pulmonary Fibrosis: What We Have Learnt from Other Tissues

Guest Editor:

Dr. Steven E. Mutsaers
Institute for Respiratory Health, University of Western Australia, Perth, Australia

Deadline for manuscript submissions:
closed (31 October 2022)

Message from the Guest Editor

Dear Colleagues,

There is a growing interest from the pharmaceutical industry to develop drugs to treat fibrotic diseases. Until recently, diseases such as idiopathic pulmonary fibrosis have had no effective treatments. However, the development of pirfenidone and nintedanib has renewed enthusiasm for developing better drugs that not only slow down the fibrotic response but reverse fibrosis. However, to develop more effective treatments, we first need to better understand disease pathogenesis. There is a growing literature on the pathogenesis of lung fibrosis using cells, tissues and fluids from patients and animal models. There is also a vast amount of data generated from studies examining disease mechanisms in other fibrotic conditions. The focus of this Special Issue will be to examine what we have learnt about the mechanisms driving fibrosis in other tissues and diseases to help us delineate the mechanisms driving fibrosis in the lung.

biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI